Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The ROADMAP project launches its Data Cube. The Cube offers a dynamic overview of the ‘landscape’ of data availability in Europe for Alzheimer’s disease research.

Funded through the Innovative Medicines Initiative, the public-private Real world outcomes across the Alzheimer's Disease spectrum for better care: Multi-modal data Access Platform (ROADMAP) project brought together 26 organisations led by Novartis and coordinated by the University of Oxford.

One of the partnership's main aspirations was to support the identification and integration of realworld data across multiple sources and countries. Through that, it intended to support opportunities for the development of evidence for the reimbursement and access of new technologies for the treatment of Alzheimer's disease (AD), ultimately aiming to drive healthcare systems towards better care and data capture.

The consortium therefore collaboratively developed this 3D 'heat map' assessment. It allows the visualisation of the different data sources and how they are able to capture different AD-outcomes together with their relevance for the different disease stages. Users can switch between the perspectives of people with dementia, carers and health professionals. Enabling the visualisation of the AD-related data availability in different types of European data
sources and the intrinsic gaps, has proven to be a powerful tool for the design, planning and validation of the models and strategies used to guide future recommendations to enhance AD research.

Through these efforts, ROADMAP helps address the challenge of how best to inform clinical and health-policy decisions by studying how to build a population-based integrated data environment and enabling its visualisation. The online version of the Data Cube is available here: https://datacube.roadmap-alzheimer.org.

The Data Cube is an important outcome of the ROADMAP project as it provides a much needed, overarching picture of priority outcomes, across the disease stages, and whether data is available. It helps to identify gaps in the evidence and provides a useful tool for regulatory and HTA purposes. - Dr Jacoline Bouvy, Senior Scientific Adviser, NICE

Similar stories

New study shows higher rate of fractures in people with intellectual disability

In the most comprehensive study of its kind, researchers at the University of Oxford and Oxford Health NHS Foundation Trust found a substantially higher rate of fractures in people with intellectual disability compared with people of the same age and gender without an intellectual disability

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Inside the Wade-Martins Lab for World Alzheimer’s Day 2022

This week DPAG marked World Alzheimer's Day, which took place on Wednesday 21 September 2022, with an inside look into the Wade-Martins Laboratory.

Engagement with arts and culture can have a positive impact on mental health in young people

A new study finds that engaging with arts and culture online can improve mental health in young people.

Novel Use of Ultrasound-Guided Fine Needle Aspiration of Lymph Nodes Helps Scientists Study Brain and Immunity

A new study investigates immune mechanisms that underlie a brain disease called NMDAR-antibody encephalitis, an autoimmune disease in which antibodies are produced, and subsequently disrupt brain NMDA receptors, crucial in maintaining normal brain function.